Idarubicin combined chemotherapy regimen for 22 cases with refractory or relapsed multiple myeloma / 中国癌症杂志
China Oncology
;
(12)1998.
Artículo
en Chino
| WPRIM
| ID: wpr-536601
ABSTRACT
Purpose:
To study the efficacy and toxicity of VIDM regimen (vincristine,idarubicin,dexamethasone and melphalan) for refractory or relapsed multiple myeloma(MM).Methods:
45 refractory or relapsed MM patients were randomized into two groups VIDM group(treatment group) had 22 patients treated with VIDM regimen, VAD group(control group) had 23 patients with VAD regimen.Results:
The effective rate with VIDM regimen (59.1%) was significantly higher than that of VAD regimen (26.1%) (P
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Chino
Revista:
China Oncology
Año:
1998
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS